Maha Hussain

Maha Hussain

UNVERIFIED PROFILE

Are you Maha Hussain?   Register this Author

Register author
Maha Hussain

Maha Hussain

Publications by authors named "Maha Hussain"

Are you Maha Hussain?   Register this Author

100Publications

3030Reads

5Profile Views

Inflammatory Bowel Disease and the Risk of Prostate Cancer.

Eur Urol 2019 05 4;75(5):846-852. Epub 2018 Dec 4.

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.11.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542355PMC
May 2019

Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?

Eur Urol Focus 2019 03 23;5(2):125-133. Epub 2019 Feb 23.

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.02.006DOI Listing
March 2019

Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

Transl Androl Urol 2019 Mar;8(Suppl 1):S91-S92

Division of Hematology/Oncology, Department of Internal Medicine, Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2018.12.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511695PMC
March 2019

Enzalutamide in Castration-Resistant Prostate Cancer.

N Engl J Med 2018 10;379(14):1381

San Camillo Forlanini Hospital, Rome, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1810065DOI Listing
October 2018

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med 2018 Jun;378(26):2465-2474

From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1800536DOI Listing
June 2018

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

J Clin Oncol 2018 05 6;36(15):1498-1504. Epub 2018 Apr 6.

Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Catherine M. Tangen, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Ian M. Thompson Jr, University of Texas Health Science Center, San Antonio; Gregory P. Swanson, Baylor Scott and White Health, Temple, TX; David P. Wood, Beaumont Physician Partners and Clinical Faculty, Royal Oak; Wael Sakr, Wayne State University School of Medicine, Detroit, MI; Nancy A. Dawson, Lombardi Comprehensive Cancer Center, Washington, DC; Naomi B. Haas, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Thomas W. Flaig, E. David Crawford, and L. Michael Glode, University of Colorado Cancer Center, Denver, CO; Tanya B. Dorff and David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; and Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959197PMC
May 2018

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

J Clin Oncol 2018 04 20;36(10):991-999. Epub 2017 Dec 20.

Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University; Walter M. Stadler, University of Chicago, Chicago; Daniel H. Shevrin, NorthShore University Health System, Evanston, IL; Maha Hussain, Stephanie Daignault-Newton, Lakshmi P. Kunju, Javed Siddiqui, Yi-Mi Wu, Dan Robinson, Robert J. Lonigro, Xuhong Cao, Scott A. Tomlins, Rohit Mehra, David C. Smith, Megan V. Caram, and Arul M. Chinnaiyan, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Przemyslaw W. Twardowski, City of Hope Cancer Center, Duarte; Felix Y. Feng, University of California San Francisco, San Francisco, CA; Costantine Albany, Simon Cancer Center, Indiana University, Indianapolis, IN; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Kathleen A. Cooney, University of Utah, Salt Lake City, UT; Bruce Montgomery, University of Washington, Seattle, WA; Emmanuel S. Antonarakis, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Paul G. Corn, University of Texas MD Anderson Cancer Center, Houston, TX; Young E. Whang, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and Karen E. Knudsen, Thomas Jefferson University, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.7310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075827PMC
April 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

J Clin Oncol 2018 04 5;36(10):937-941. Epub 2018 Feb 5.

Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4050DOI Listing
April 2018

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

J Clin Oncol 2018 04 9;36(11):1088-1095. Epub 2018 Mar 9.

Alicia K. Morgans, Maha Hussain, and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Yu-Hui Chen and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; David F. Jarrard, University of Wisconsin Hospital and Clinics, Madison, WI; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Elizabeth R. Plimack and Benjamin A. Gartrell, Montefiore Medical Center, Bronx, NY; Michael A. Carducci, Johns Hopkins University, Baltimore, MD; Jorge A. Garcia, Cleveland Clinic, Cleveland, OH; Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY; and Linda J. Patrick-Miller, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891128PMC
April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Risk stratification in oligometastatic prostate cancer: where are we and what do we need?

Curr Opin Urol 2017 Nov;27(6):547-552

aRobert H. Lurie Comprehensive Cancer Center bNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00042307-201711000-0000
Publisher Site
http://dx.doi.org/10.1097/MOU.0000000000000439DOI Listing
November 2017

The role of genomics in patients with advanced prostate cancer.

Authors:
Maha H Hussain

Clin Adv Hematol Oncol 2017 Oct;15(10):770-772

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
October 2017

Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.

Cancer J 2016 Sep/Oct;22(5):326-329

From the *Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; and †Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000214DOI Listing
August 2017

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.

Cancer 2017 06 21;123(11):1912-1924. Epub 2017 Mar 21.

Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457906PMC
June 2017

Intermittent Androgen Deprivation: Primum Non Nocere-"First Do NO Harm".

JAMA Oncol 2016 Dec;2(12):1533-1534

Johns Hopkins Sidney Kimmel Cancer Center, Oncology, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2650DOI Listing
December 2016

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.

Oncology (Williston Park) 2016 May;30(5):377-85

View Article

Download full-text PDF

Source
May 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Clinical research in metastatic prostate cancer: a focus on impact and value.

Am Soc Clin Oncol Educ Book 2015 :17-21

From the University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.17DOI Listing
February 2016

Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer.

Am Soc Clin Oncol Educ Book 2015 :e263-9

From the Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/11500263-156
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e263DOI Listing
February 2016

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

J Clin Oncol 2016 Jan 9;34(3):280-5. Epub 2015 Nov 9.

Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Catherine Tangen, SWOG Statistical Center; Celestia Higano, University of Washington, Seattle, WA; Nicholas Vogelzang, US Oncology, Las Vegas, NV; and Ian Thompson, University of Texas Health Science Center, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.8065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242560PMC
January 2016

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

J Urol 2015 Dec 18;194(6):1537-47. Epub 2015 Jul 18.

Smilow Cancer Center, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.06.106DOI Listing
December 2015

Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer.

J Urol 2015 Sep 23;194(3):790-8. Epub 2015 Apr 23.

Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.02.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103704PMC
September 2015

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

N Engl J Med 2015 Aug 5;373(8):737-46. Epub 2015 Aug 5.

From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1503747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797PMC
August 2015

Addressing apoptosis to tumor zip codes.

Cancer 2015 Jul 1;121(14):2296-9. Epub 2015 Apr 1.

Division of Hematology/Oncology, Department of Internal Medicine and University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29346DOI Listing
July 2015

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol 2015 May 6;33(14):1601-8. Epub 2015 Apr 6.

Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417730PMC
May 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

J Clin Oncol 2014 Oct 15;32(30):3391-9. Epub 2014 Sep 15.

Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/09/15/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.5954
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383838PMC
October 2014

Bladder cancer: bladder preservation--learning what we don't know.

Nat Rev Urol 2014 Jun 20;11(6):310-2. Epub 2014 May 20.

University of Colorado Comprehensive Cancer Center, 13001 East 17th Place, MS #F-434, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.102DOI Listing
June 2014

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

J Natl Cancer Inst 2014 Apr 24;106(4):dju013. Epub 2014 Feb 24.

Affiliations of authors: University of California Davis Comprehensive Cancer Center, Sacramento, CA (PNL, PCM); Southwest Oncology Group Statistical Center, Seattle, WA (BE, CT); University of Southern California Norris Cancer Center, Los Angeles, CA (DIQ, AG); USDA Western Human Nutrition Center at University of California Davis, Davis, CA (EG, MVL); City of Hope, Duarte, CA (PT); University of Michigan, Ann Arbor, MI (MH), US Oncology, Las Vegas, NV (NJV); Cancer Treatment and Research Center, University of Texas, San Antonio, TX (IT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982883PMC
April 2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Apr 10;32(11):1136-42. Epub 2014 Mar 10.

Amir Goldkorn, David I. Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles; Przemyslaw Twardowski, City of Hope, Duarte; Philip C. Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA; Benjamin Ely and Catherine M. Tangen, Southwest Oncology Group Statistical Center; Celestia S. Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA; Louis M. Fink, Nevada Cancer Institute; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV; Peter J. Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Michael A. Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD; J. Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH; Ram H. Datar and Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL; Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, OR; Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Ian Murchie Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.7417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970171PMC
April 2014

Intermittent androgen deprivation therapy in advanced prostate cancer.

Curr Treat Options Oncol 2014 Mar;15(1):127-36

University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 7314, Ann Arbor, MI, 48109-5946, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-013-0272-2DOI Listing
March 2014

Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.

Invest New Drugs 2014 Feb 10;32(1):188-94. Epub 2013 Dec 10.

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0054-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108360PMC
February 2014

Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

Eur Urol 2014 Feb;65(2):501

University of Colorado Comprehensive Cancer Center, Aurora, CO, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838130119
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2013.10.054DOI Listing
February 2014

Management of hormone-sensitive metastatic prostate cancer.

Hematol Oncol Clin North Am 2013 Dec 21;27(6):1221-41, viii. Epub 2013 Sep 21.

Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2123, Salt Lake City, UT 84112, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588130011
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2013.08.007DOI Listing
December 2013

Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.

Mol Med 2013 Nov 8;19:367-76. Epub 2013 Nov 8.

Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America Translational Oncology Program, University of Michigan, Ann Arbor, Michigan, United States of America University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2119/molmed.2013.00108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883970PMC
November 2013

Castration-resistant prostate cancer: AUA Guideline.

J Urol 2013 Aug 9;190(2):429-38. Epub 2013 May 9.

American Urological Association Education and Research, Inc., Linthicum, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2013.05.005DOI Listing
August 2013

The changing natural history of metastatic prostate cancer.

Cancer J 2013 Jan-Feb;19(1):19-24

Division of Hematology/Oncology, Department of Internal Medicine, and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318281197eDOI Listing
July 2013

Non-castrate metastatic prostate cancer: have the treatment options changed?

Semin Oncol 2013 Jun;40(3):337-46

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-5946, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009377541300065
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2013.04.007DOI Listing
June 2013

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

Curr Opin Oncol 2013 May;25(3):252-60

Division of Hematology/Oncology, Department of Internal Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835ff161DOI Listing
May 2013

Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.

Crit Rev Oncol Hematol 2013 Jan 16;85(1):82-93. Epub 2012 Jun 16.

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2012.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940154PMC
January 2013

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

Invest New Drugs 2012 Feb 5;30(1):249-57. Epub 2010 Aug 5.

Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, 3rd floor, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9503-6DOI Listing
February 2012

Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.

Cancer 2012 Jan 19;118(1):44-53. Epub 2011 May 19.

Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26240DOI Listing
January 2012

New therapies for castration-resistant prostate cancer: efficacy and safety.

Eur Urol 2011 Aug 4;60(2):279-90. Epub 2011 May 4.

Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2011.04.038DOI Listing
August 2011

Urothelial carcinomas: a focus on human epidermal receptors signaling.

Am J Transl Res 2011 Aug 25;3(4):362-73. Epub 2011 Jul 25.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158738PMC
August 2011

Evolving therapeutic paradigms for advanced prostate cancer.

Oncology (Williston Park) 2011 May;25(6):496-504, 508

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109-5946, USA.

View Article

Download full-text PDF

Source
May 2011

Management of bladder cancer: current and emerging strategies.

Drugs 2009 Jun;69(9):1173-87

Huntsman Cancer Institute at the University of Utah, Salt Lake City, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200969090-00003DOI Listing
June 2009

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

J Natl Cancer Inst 2009 Feb 10;101(4):228-36. Epub 2009 Feb 10.

Radiology Associates of Appleton, Appleton, WI 54911, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djn489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734115PMC
February 2009